What We Do

Who We Are

Well Cell® is a privately held family of companies led by Well Cell Global LLC, a research and development biotech healthcare organization headquartered in Houston, Texas. We operate at the intersection of clinical research, intellectual property, and physician-directed care.

Well Cell® is the global leader in Glucose Metabolism Optimization℠ and the developer, licensor, and steward of Physiologic Insulin Resensitization® (PIR®). Our work is grounded in issued U.S. patents and international intellectual property protections, reflecting years of focused research and development.

What is PIR®

PIR® is a treatment designed to help physicians improve metabolic health:

PIR® uses insulin as a hormone, not a symptom suppressant.
Helps improve insulin sensitivity and reduce insulin resistance.
Positive results at the cellular level, not just symptom management.
Reported benefits: neuropathy, nephropathy, retinopathy, wound healing.

Island Doctors in Florida have reported significant kidney function improvements among patients using the PIR® method. These outcomes are gaining attention from healthcare providers globally.

Post-PIR Care Plan*

*p < 0.001 Patient “n=66” Island Doctors Sample (Dec 3, 2024)

90,91%

Kidney Function Stabilized or Improved

Peer-Reviewed PIR® Publications

Physologic Insulin Resensitization Lowers Cost in Patients With Diabetes and Kidney Disease

Effect of Physiologic Insulin Resensitization on Stages of Chronic Kidney Disease

We Empower Healthcare Professionals to
‍Grow Their Clinical Practice

Research & Development

Advancing clinical and scientific progress through validated data and peer-reviewed publications.

Clinical Research

Benchtop Research

Clinical Research

Licensing

Protocol and equipment for physicians’ treatment of metabolic disorder

Hormonal Specialized Training

Specialized education on insulin used as a hormone rather than a drug™ to improve resistance and treat diabetes.

Clinical Trial-Grade Evidence

Built on peer-reviewed research and validated methodologies aligned with clinical trial rigor.

Global Healthcare Network

Collaboration across physicians, institutions, and research partners to support consistent, evidence-driven care worldwide.

Advising businesses about PIR® services

Glenn Massey

Chief Growth Officer

Reach Out to our Chief
Growth Officer

Glenn Massey

Chief Growth Officer

glenn@wellcellglobal.com

welcome to well cell

Want to Explore PIR®?

Please fill out the form below with your contact information. We’ll get back to you as soon as possible!